Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

2590 PWToday Stories

Novimmune grants Tiziana an exclusive license to NI-1201, an anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.

04 Jan 17

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, and Tiziana Life Sciences (TILS), have signed a second collaboration agreement granting Tiziana exclusive rights to develop and commercialize its anti-IL-6R monoclonal antibody, NI-1201.


Anti-IL6R antibodies are marketed or in development for a range of inflammatory conditions including rheumatoid arthritis. Tiziana intends to explore the development of NI-1201 in Non-alcoholic Steato hepatitis (NASH), diabetes and other life threatening inflammatory diseases, as well as foralumab (NI-0401), the first antibody that Novimmune licensed to Tiziana in December 2014. Financial details were not disclosed.


“Two years ago, we entered into our first collaboration with Tiziana and we have been very pleased with the progress they have made with NI-0401, currently in phase 2 clinical development. We are delighted to have signed this second agreement to move NI-1201 forward, and we believe this is a very exciting molecule which complements Tiziana’s portfolio.” said Novimmune Chairman and Chief Executive Officer, Eduard Holdener.

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.